Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Aronora (Details)

v3.22.1
Royalty and Commercial Payment Purchase Agreements - Aronora (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Apr. 07, 2019
USD ($)
item
Sep. 30, 2019
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Agreements        
Long-term royalty and commercial payment receivables     $ 69,075 $ 69,075
Contingent consideration under RPAs and CPPAs     3,075 8,075
Impairment of long-term royalty receivable     0 $ 0
Aronora | Royalty Purchase Agreement        
Agreements        
Number of drug candidates | item 5      
Non-royalties to be received (as a percent) 10.00%      
Future non-royalty payments to be received (as a percent) 5.00%      
Multiplier for cumulative amount of consideration paid | item 2      
Upfront payment $ 6,000      
Threshold amount of cumulative royalties on net sales per product 250,000      
Aggregate milestones payments per product 85,000      
Long-term royalty and commercial payment receivables 9,000      
Contingent consideration under RPAs and CPPAs 3,000      
Payments of contingent consideration   $ 3,000    
Impairment of long-term royalty receivable     $ 0  
Aronora | Royalty Purchase Agreement | SVB Loan        
Agreements        
Upfront payment $ 3,000      
Aronora | Royalty Purchase Agreement | Bayer Products        
Agreements        
Number of drug candidates | item 3      
Number of drug candidates subject to exclusive license option | item 1      
Royalties entity has right to receive (as a percent) 100.00%      
Non-royalties to be received (as a percent) 10.00%      
Contingent future cash payment for each product $ 1,000      
Potential future cash payments $ 3,000      
Aronora | Royalty Purchase Agreement | Non-Bayer Products        
Agreements        
Number of drug candidates | item 2      
Non-royalties to be received (as a percent) 10.00%